E-therapeutics PLC (LON:ETX) appointed Dr Karl Keegan as its new Chief Financial Officer (CFO) effective immediately.
Keegan has worked for more than 20 years in the pharmaceutical and biotech industries, said e-therapeutics, including in academia, large pharma and as a sell-side analyst at a number of investment banks.
Since 2009, he has held senior executive roles in private and public companies, most recently as chief executive officer of privately held Hox Therapeutics Limited.
Keegan said: "I am delighted to be joining the e-therapeutics team at such a pivotal time for the company. The company has built an impressive computational biology drug discovery platform and clinically validated RNA interference drug modality."
Ali Mortazavi, Chief Executive Officer, commented: "We are delighted to welcome Karl to e-therapeutics at this point in the company's evolution. The combination of his industry and financial sector expertise will be a major addition to the team."
The CFO role will be a non-board position.